Conference Dates
June 12 – 17, 2022
Abstract
Influenza virus infects millions of people every year worldwide, with elderly and very young people among the most critically affected. Strains that constitute a pandemic threat are characterized by the severity of the clinical manifestations and mortality rates and tend to require the urgent production of hundreds of millions of vaccine doses in very short periods of time. There is an evident need to develop new generations of influenza vaccines based on robust production systems such as mammalian or insect cell cultures. These systems may allow, in contrast to production in embryonated chicken eggs, a faster response capacity, a superior manufacturing process control and a more reliable and better characterized product.
Please click Download on the upper right corner to see the full abstract.
Recommended Citation
Amine Kamen, Cécile Toussaint, Omar Farnos, David Sharon, Alina Venereo-Sanchez, Irene González-Domínguez, Alice Bernier, Xingge Xu, and Hanan Chaabane, "Multivalent Influenza vaccine production in HEK-293 cells in response to pandemic threats" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/123